Centre on Aging and Mobility, University of Zurich and Waid City Hospital Zurich, Zurich, Switzerland.
J Bone Miner Res. 2012 Jan;27(1):160-9. doi: 10.1002/jbmr.551.
To test the effect of 25(OH)D(3) (HyD) compared to vitamin D(3) on serum 25-hydroxyvitamin D levels (25(OH)D), lower extremity function, blood pressure, and markers of innate immunity. Twenty healthy postmenopausal women with an average 25(OH)D level of 13.2 ± 3.9 ng/mL (mean ± SD) and a mean age of 61.5 ± 7.2 years were randomized to either 20 µg of HyD or 20 µg (800 IU) of vitamin D(3) per day in a double-blind manner. We measured on 14 visits over 4 months, 25(OH)D serum levels, blood pressure, and seven markers of innate immunity (eotaxin, interleukin [IL]-8, IL-12, interferon gamma-induced protein 10 kDa [IP-10], monocyte chemotactic protein-1 [MCP-1], macrophage inflammatory protein beta [MIP-1β], and "Regulated upon Activation, Normal T-cell Expressed, and Secreted" [RANTES]). At baseline and at 4 months, a test battery for lower extremity function (knee extensor and flexor strength, timed up and go, repeated sit-to-stand) was assessed. All analyses were adjusted for baseline measurement, age, and body mass index. Mean 25(OH)D levels increased to 69.5 ng/mL in the HyD group. This rise was immediate and sustained. Mean 25(OH)D levels increased to 31.0 ng/mL with a slow increase in the vitamin D(3) group. Women on HyD compared with vitamin D(3) had a 2.8-fold increased odds of maintained or improved lower extremity function (odds ratio [OR] = 2.79; 95% confidence interval [CI], 1.18-6.58), and a 5.7-mmHg decrease in systolic blood pressure (p = 0.0002). Both types of vitamin D contributed to a decrease in five out of seven markers of innate immunity, significantly more pronounced with HyD for eotaxin, IL-12, MCP-1, and MIP-1 β. There were no cases of hypercalcemia at any time point. Twenty micrograms (20 µg) of HyD per day resulted in a safe, immediate, and sustained increase in 25(OH)D serum levels in all participants, which may explain its significant benefit on lower extremity function, systolic blood pressure, and innate immune response compared with vitamin D(3).
比较 25-羟维生素 D3（25（OH）D）与维生素 D3 对血清 25-羟维生素 D 水平（25（OH）D）、下肢功能、血压和固有免疫标志物的影响。
20 名平均年龄 61.5±7.2 岁的绝经后健康女性，平均 25（OH）D 水平为 13.2±3.9ng/ml（均数±标准差），随机分为每日 20μg HyD 或 20μg（800IU）维生素 D3 组，采用双盲法。在 4 个月的 14 次就诊中，我们测量了血清 25（OH）D 水平、血压和 7 种固有免疫标志物（嗜酸性粒细胞趋化因子、白细胞介素[IL]-8、IL-12、γ-干扰素诱导蛋白 10kDa[IP-10]、单核细胞趋化蛋白-1[MCP-1]、巨噬细胞炎症蛋白-β[MIP-1β]和“活化正常 T 细胞表达和分泌”[RANTES]）。在基线和 4 个月时，评估了下肢功能（膝关节伸肌和屈肌力量、计时上下、重复坐站）测试套件。所有分析均根据基线测量、年龄和体重指数进行调整。HyD 组的平均 25（OH）D 水平升高至 69.5ng/ml。这种升高是即时的且持续的。维生素 D3 组的 25（OH）D 水平缓慢升高至 31.0ng/ml。与维生素 D3 相比，服用 HyD 的女性保持或改善下肢功能的几率增加了 2.8 倍（优势比[OR]=2.79；95%置信区间[CI]，1.18-6.58），收缩压降低 5.7mmHg（p=0.0002）。两种类型的维生素 D 均导致 7 种固有免疫标志物中的 5 种标志物下降，HyD 对嗜酸性粒细胞趋化因子、IL-12、MCP-1 和 MIP-1β 的影响更为显著。在任何时间点均未发生高钙血症。每天 20μg HyD 可使所有参与者的血清 25（OH）D 水平安全、即时和持续升高，这可能解释了与维生素 D3 相比，它对下肢功能、收缩压和固有免疫反应的显著益处。
